Summary

For patients with a history of myocardial infarction (MI) who are stable, the addition of vorapaxar to the standard of care reduced the long-term risk of cardiovascular death or ischemic events and increased the risk of moderate or severe bleeding. The efficacy and safety of the drug were evaluated for secondary prevention in a broad group of patients with prior MI, prior stroke, or peripheral artery disease in the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction 50 [TRA 2°P-TIMI 50] trial.